Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Gross Profit (2017 - 2025)

Historic Gross Profit for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to $24.2 million.

  • UroGen Pharma's Gross Profit rose 638.65% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.9 million, marking a year-over-year increase of 523.14%. This contributed to the annual value of $81.5 million for FY2024, which is 1113.13% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Gross Profit is $24.2 million, which was up 638.65% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Gross Profit ranged from a high of $24.2 million in Q3 2025 and a low of $6.6 million during Q1 2021
  • Moreover, its 5-year median value for Gross Profit was $17.1 million (2024), whereas its average is $16.7 million.
  • Its Gross Profit has fluctuated over the past 5 years, first surged by 348179.01% in 2021, then skyrocketed by 400.11% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Gross Profit stood at $14.6 million in 2021, then increased by 8.53% to $15.8 million in 2022, then soared by 34.21% to $21.2 million in 2023, then rose by 4.0% to $22.1 million in 2024, then grew by 9.55% to $24.2 million in 2025.
  • Its Gross Profit stands at $24.2 million for Q3 2025, versus $20.7 million for Q2 2025 and $17.9 million for Q1 2025.